SCHEMBL31270666

SCHEMBL31270666

CCCCc1nc2c(NC(C)(C)C)nc3cc(C4CCOCC4)sc3c2n1CC1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 3/20 0.38
GLS O94925 2/20 0.36
THRB P10828 3/20 0.35
LMNA P02545 3/20 0.34
TLR8 Q9NR97 1/20 0.34
RORC P51449 1/20 0.34
GPR119 Q8TDV5 1/20 0.33
MERTK Q12866 1/20 0.33
EED O75530 1/20 0.33
RBBP4 Q09028 1/20 0.33
SUZ12 Q15022 1/20 0.33
EZH2 Q15910 1/20 0.33
AEBP2 Q6ZN18 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25257815 1.00 TLR7 (0.38) TLR7GLSTHRBLMNATLR8
SCHEMBL25296097 0.98 TLR7 (0.40) TLR7GLSTHRBLMNATLR8
SCHEMBL31025940 0.98 TLR7 (0.40) TLR7GLSTHRBLMNATLR8
SCHEMBL31270541 0.93 GLS (0.37) GLSTHRBLMNARORCGPR119
SCHEMBL25256981 0.93 GLS (0.37) GLSTHRBLMNARORCGPR119
SCHEMBL25256345 0.92 GLS (0.36) GLSTHRBLMNARORCGPR119
SCHEMBL31270667 0.92 GLS (0.36) GLSTHRBLMNARORCGPR119
SCHEMBL25258659 0.89 LMNA (0.39) GLSTHRBLMNA
SCHEMBL25255314 0.89 LMNA (0.39) GLSTHRBLMNA
SCHEMBL31270728 0.89 LMNA (0.39) GLSTHRBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260055119-A9 TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) 2026-02-26 US disclosed
US-20250257071-A9 TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2025-08-14 US disclosed
US-20250002502-A1 TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) 2025-01-02 US disclosed
EP-4458830-A1 TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2024-11-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250257071-A9 TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF CYP11B2, CYP11B1, CYP3A5 TLR7 2484/4885GLS 3387/4885THRB 2257/4885
US-20260055119-A9 TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF CYP11B1, CYP11B2, CYP2D6 TLR7 2700/4885GLS 3545/4885THRB 1492/4885
US-20250002502-A1 TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF CYP11B2, CYP11B1, CYP3A5 TLR7 2484/4885GLS 3387/4885THRB 2257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.